Atlas Trials

Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes

Clinical trial NCT04893135 · COMPLETED

Trial details

NCT number
NCT04893135
Sponsor
Centre Hospitalier Sud Francilien
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Type II Diabetes
Start date
2021-10-11
Primary completion
2022-10-11
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.